Narrative review / 2012
Targeting methionine auxotrophy via methionine-depleting drugs is being explored as a potential therapeutic approach against cancer.
This review explores the discovery of methionine auxotrophy alongside in vitro, in vivo, and patient data on targeting cancer via methionine depletion. It also discusses mechanisms such as bioengineering, pegylation, and red blood cell encapsulation to decrease the immunogenicity of methionine-depleting drugs. The authors note that extensive research is still needed on normal versus cancer cell toxicity, molecular mechanisms, and methods to lower immunogenicity.
- Study type
- Narrative review
- Who was studied
- Cancer patients, in vitro, and in vivo models
- What was measured
- Efficacy, toxicity, and immunogenicity of methionine depletion therapy
THE PAPER
Targeting methionine auxotrophy in cancer: discovery & exploration.
Agrawal V, Alpini SE, Stone EM, Frenkel EP, Frankel AE. Expert Opin Biol Ther, 2012.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.